Teva Expects To Carve Out Sizable Niche For Uzedy In Antipsychotic Market
Long-Acting Injectable Adds To Franchise
Uzedy was recently approved by the US FDA as an extended-release subcutaneous formula of risperidone; it is poised to be a new prong in Teva’s branded portfolio.
You may also be interested in...
Teva: Our Biosimilars Strategy Has Been Fragmented, We Want To Be Global
Months into the job, Teva CEO Richard Francis delivered the company’s promise for a new dedicated strategy to return to growth. Funded by a portion of capital reallocated from Teva’s generics business to focus on innovative brands, the new strategy will continue to promote biosimilars, Teva has outlined.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: J&J’s Duarto on the importance of diversity; Teva’s views on its new risperidone launch; Almirall’s hopes for lebrikizumab; Biogen’s Viehbacher questions the need for spending on weight loss drugs; and Citeline’s annual R&D review looks at the current state of the global biopharma pipeline.
Francis Takes Stock Of Teva Ahead Of Revealing Fresh Strategy
As Teva prepares to unveil a fresh strategy under new CEO Richard Francis on 18 May, the company has delivered Q1 results along with an update on planned US launches for long-acting injectable risperidone as well as biosimilar adalimumab.